AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
Read more at MarketWatch
-
Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
Business - MarketWatch - November 11 -
AbbVie shares tumble after schizophrenia drug disappoints
Business - Financial Times - November 11 -
Google’s AI-Fueled Results Bode Well for Rivals Amazon and Microsoft
Business - Inc. - October 30 -
Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs
Business - CNBC - October 31 -
Bristol Myers’s stock pops as earnings top estimates and company raises guidance
Business - MarketWatch - October 31 -
An Australian on trial for drugs in Japan says she's the victim of a romance scam
World - ABC News - 3 days ago -
A promising schizophrenia drug showed mixed results. What does that mean for patients?
Health - ABC News - October 31 -
Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation
Business - MarketWatch - Yesterday
More from MarketWatch
-
Analysts don’t budge on Williams-Sonoma ratings despite stock rally
Business - MarketWatch - 4 minutes ago -
Is higher inflation here to stay? Fed faces hurdles in quest to crush rising prices.
Business - MarketWatch - 13 minutes ago -
Treasury yields steady as traders weigh increased Russia-Ukraine tensions
Business - MarketWatch - 14 minutes ago -
Philadelphia Fed’s manufacturing gauge shows activity contracted in November
Business - MarketWatch - 20 minutes ago -
MicroStrategy’s stock could do something it hasn’t done in 24 years as bitcoin surges
Business - MarketWatch - 33 minutes ago